Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumours

Official Title

A Phase 1 First-in Human, Multi-Centre, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumours

Summary:

The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with budigalimab. The study will consist of 2 phases: dose escalation and dose expansion.

Trial Description

Primary Outcome:

  • Dose Escalation: Recommended Phase 2 Dose (RP2D) ABBV-151 Monotherapy
  • Dose Escalation: RP2D ABBV-151 + Budigalimab Combination Therapy
  • Dose Expansion: Objective Response Rate (ORR)
Secondary Outcome:
  • Dose Expansion: Duration of Response (DOR)
  • Dose Expansion: Progression-free Survival (PFS)
  • Maximum Observed Serum Concentration (Cmax) of ABBV-151
  • Time to Maximum Observed Serum Concentration (Tmax) of ABBV-151
  • Area Under the Plasma Concentration-time Curve over time from 0 to last measurable concentration (AUCτ) of ABBV-151
  • Terminal-phase Elimination Rate Constant (β) of ABBV-151
  • Terminal Phase Elimination Half-life (t1/2) of ABBV-151
  • Maximum Observed Serum Concentration (Cmax) of Budigalimab
  • Time to Maximum Observed Serum Concentration (Tmax) of Budigalimab
  • Area Under the Plasma Concentration-time Curve over time from 0 to last measurable concentration (AUCτ) of Budigalimab
  • Terminal-phase Elimination Rate Constant (β) of Budigalimab
  • Terminal Phase Elimination Half-life (t1/2) of Budigalimab
  • Number of Participants With Adverse Events (AEs)
  • Change in Vital Signs
  • Change in Laboratory Parameters
  • Change in Electrocardiogram (ECG)
  • Incidence of Anti-drug Antibody (ADA)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society